Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Supply chain

Drug wholesalers discuss contingency plans with government to prepare for 'no-deal' Brexit

The Healthcare Distribution Association has said current preparations to build up buffer stocks in case of a ‘no-deal’ Brexit scenario mirror those of a flu pandemic.

Martin Sawer, executive director at the Healthcare Distribution Authority

Source: Courtesy, Healthcare Distribution Association

It is likely that wholesalers will request extra stock from pre-wholesalers in the early months of 2019, before the UK leaves the EU on 29 March 2019, Martin Sawer has said

The Healthcare Distribution Association (HDA), which represents drug wholesalers and distributors, has already met with the Department of Health and Social Care (DHSC) to discuss contingency measures in the event of a “no-deal” Brexit, its executive director has told The Pharmaceutical Journal.

“We are talking to the government to try and assess what the preparedness state is at the moment [in the event of a no deal],” Martin Sawer, executive director at the HDA, has said.

“It’s about understanding the capacity of the UK market and building up a buffer stock should there be a no-deal scenario. Communication is going to be key.”

Sawer said that the current discussions and moves being suggested mirror those which would traditionally happen in anticipation of a pandemic flu outbreak, or the steps that were taken across the sector around potential medicine demand before the Olympic Games in London in 2012.

He said it is likely that wholesalers will request extra stock from their pre-wholesaler suppliers from January 2019 until March 2019, when the UK is scheduled to depart the EU.

“The other role we have is to talk to the pre-wholesalers, who supply wholesalers, to ‘sensitise’ them to our demands and quantities of medicines that we need, so that there aren’t any gaps [in the supply chain],” he said.

Sawer was unable to predict which specific extra drug stock might be needed and expected that decision would be down to the DHSC. 

“Each medicine will be looked at in terms of its route and how it will get to pharmacies — the devil will be in the detail.

“The government is doing the best that it can and it would be irresponsible if it was not doing any planning in the event of a no deal.

“One person not getting their critical medicine if there is no deal is one person too many.”

On 24 July 2018, health and social care secretary Matt Hancock told a meeting of the House of Commons health select committee that he had asked civil servants to “accelerate” plans, including preparation for the potential need for stockpiling of drugs, to deal with the consequences of the UK leaving the EU in 2019 with no agreement in place.

President of the Royal Pharmaceutical Society (RPS), Ash Soni, said that the risk of the Brexit resulting in delays in patients accessing medicines was a concern widely recognised across the healthcare sector.

“With some medicines manufacturers now talking about contingency plans to stockpile medicines in the absence of a negotiated deal, we are engaging with regulators and the NHS about their plans to minimise any potential disruption to the medicines supply chain.

“It’s understandable that current uncertainties about Brexit are raising concerns about patient care. Ultimately, I’m confident that pharmacists will continue to ensure that patient safety remains their top priority, and that the RPS will be on hand to help the profession manage future changes.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2018.20205242

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Essentials of Economic Evaluation in Healthcare

    Essentials of Economic Evaluation in Healthcare

    An introduction to economic evaluation specific to healthcare, for those with little or no knowledge of economics. Covers cost effectiveness, cost utility and cost benefit analysis.

    £33.00Buy now
  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Martin Sawer, executive director at the Healthcare Distribution Association

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.